natgillin/translations-raw huggingface dataset:
The rate (95% confidence interval) of lymphomas was 0.7 (0.2, 2.7) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patient-years among control patients. 
Delež (95 % interval zaupanja) limfomov je bil 0,7 (0,2; 2,7) na 1000 bolnikov-let med bolniki, ki so dobivali zdravilo Humira, in 0,6 (0,1; 4,5) na 1000 bolnikov-let v kontrolni skupini bolnikov.
Table 14 Efficacy Response in Placebo-Controlled Study nr-axSpA I 
Preglednica 14 Odziv učinkovitosti v s placebom kontrolirani študiji nr-axSpA I
Always use this medicine exactly as your child's doctor or pharmacist has instructed. 
Pri uporabi tega zdravila natančno upoštevajte navodila otrokovega zdravnika ali farmacevta.
The long halflife of adalimumab should be taken into consideration if a surgical procedure is planned. 
Če je predviden kirurški poseg, je treba upoštevati dolg razpolovni čas adalimumaba.
At Week 12, a significantly higher proportion of patients treated with Humira versus placebo achieved HiSCR. 
V 12. tednu je statistično pomembno večji delež bolnikov, ki so prejemali zdravilo Humira, doseglo klinični odziv (HiSCR) v primerjavi z bolniki, ki so prejemali placebo.
• elevated bilirubin measurement (liver blood test) 
• povečane vrednosti bilirubina (krvni test jetrne funkcije)
• respiratory tract infections (including cold, runny nose, sinus infection, pneumonia) 
• okužbe dihalnega trakta (vključno s prehladom, izcedkom iz nosu, okužbo sinusov, pljučnico)
The mean (±SD) serum adalimumab trough concentrations achieved at Week 4 were 15.7 ± 6.6 g/ml for patients ≥ 40 kg (160/80 mg) and 10.6 ± 6.1 g/ml for patients < 40 kg (80/40 mg). 
Povprečne (±SD) serumske koncentracije adalimumaba, dosežene v 4. tednu, so bile 15,7 ± 6,6 μg/ml pri bolnikih ≥ 40 kg (160/80 mg) in 10,6 ± 6.1 μg/ml pri bolnikih < 40 kg (80/40 mg).
Note: P# = Placebo (Number of Events/Number at Risk); A# = HUMIRA (Number of Events/Number at Risk). 
Opomba: P# = placebo (število dogodkov/število rizičnih preiskovancev); A# = HUMIRA (število dogodkov/število rizičnih preiskovancev).
Your doctor will decide if you should receive Humira. 
Vaš zdravnik bo odločil, ali lahko prejemate zdravilo Humira.
Humira N=208 
Zdravilo Humira n = 208
P value 
vrednost p
In patients with ankylosing spondylitis anti-adalimumab antibodies were identified in 17/204 subjects (8.3%) treated with adalimumab. 
Med bolniki z ankilozirajočim spondilitisom so protitelesa proti adalimumabu ugotovili pri 17/204 (8,3 %) tistih, ki so dobivali adalimumab.
• 160 mg at Week 0 and 80 mg at Week 2 
• 160 mg v 0. tednu in 80 mg v 2. tednu
In controlled Phase 3 trials of Humira in patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years and enthesitis-related arthritis who were 6 to 17 years, ALT elevations ≥ 3 x ULN occurred in 6.1% of Humira-treated patients and 1.3% of control-treated patients. 
V kontroliranih preskušanjih faze 3 z zdravilom Humira pri bolnikih z juvenilnim idiopatskim artritisom, ki so bili stari od 4 do 17 let in bolnikih z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, so se zvišanja ALT ≥ 3 x ULN pojavila pri 6,1 % bolnikov zdravljenih z zdravilom Humira, in pri 1,3 % bolnikov v kontrolni skupini.
Patients received placebo, an initial dose of MTX 7.5 mg and thereafter dose increases up to Week 12, with a maximum dose of 25 mg or an initial dose of 80 mg Humira followed by 40 mg every other week (starting one week after the initial dose) for 16 weeks. 
Bolniki so dobivali placebo, začetni odmerek 7,5 mg metotreksata z nadaljnjim povečanjem odmerka do 12. tedna; do največjega odmerka 25 mg, ali začetni odmerek 80 mg zdravila Humira in potem 40 mg vsak drugi teden (začenši en teden po začetnem odmerku) 16 tednov.
Table 21: Efficacy Results at 12 Weeks, HS Studies I and II HS Study I 
Preglednica 21: Rezultati učinkovitosti v 12. tednu, HS študiji I in II Študija HS I
SYRINGE LABEL 
OZNAČITEV NA BRIZGI
• abnormal muscle breakdown; 
• brazgotinjenje; • neobičajen razpad mišic;
In the pivotal trials, anti-adalimumab antibodies were identified in 5.5% (58/1053) of patients treated with adalimumab, compared to 0.5% (2/370) on placebo. 
V pivotnih preskušanjih so protitelesa proti adalimumabu odkrili pri 5,5 % (58/1053) bolnikov, ki so jih zdravili z adalimumabom v primerjavi z 0,5 % (2/370) bolnikov,
The recommended Humira induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at Week 0 followed by 40 mg at Week 2. 
Priporočena shema odmerjanja zdravila Humira med indukcijo je pri odraslih bolnikih z zmerno do hudo, aktivno Crohnovo boleznijo 80 mg 0. teden in nato 40 mg 2. teden.
The safety and efficacy of Humira in children aged 4-17 years have been established for plaque psoriasis. 
Varnost in učinkovitost zdravila Humira pri otrocih s psoriazo v plakih, starih 4-17 let, je bila potrjena.
In CD Study III, 854 patients received open-label 80 mg at Week 0 and 40 mg at Week 2. 
Crohnovi bolezni III je 854 bolnikov po odprtem protokolu dobilo 80 mg 0. teden in 40 mg 2. teden.
The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. 
Priporočeni odmerek zdravila Humira pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.
You will be instructed by your doctor or his/her assistant on the technique of self-injection. 
Zdravnik ali njegovo osebje vas bodo naučili, kako si zdravilo injicirate sami.
The apparent adalimumab plasma concentration that produces half the maximum probability of PedACR 50 response (EC50) was 3 μg/ml (95% CI: 1-6 μg/ml). 
Navidezna koncentracija adalimumaba v plazmi, ki doseže polovico največje verjetnosti Ped ACR 50 odziva (EC50) je bila
In adult patients with psoriasis, anti-adalimumab antibodies were identified in 77/920 subjects (8.4%) treated with adalimumab monotherapy. 
Pri odraslih bolnikih s psoriazo so bila protitelesa proti adalimumabu odkrita pri 77/920 oseb (8,4 %), ki so bile zdravljene z monoterapijo adalimumaba.
Table 8 Ped ACR 30 Responses in the JIA study 
Preglednica 8 Odzivi »Ped ACR« 30 v študiji pri juvenilnem idiopatskem artritisu
• certain disease-modifying anti-rheumatic agents (for example, sulfasalazine, hydroxychloroquine, 
• nekaterimi imunomodulirajočimi antirevmatičnimi zdravili (npr. sulfasalazinom,
Humira Dose for Paediatric Patients with Plaque Psoriasis 
Odmerjanje zdravila Humira pri pediatričnih bolnikih s psoriazo v plakih
The Humira pre-filled syringe is a glass syringe containing a solution of adalimumab. 
Napolnjena injekcijska brizga zdravila Humira je steklena brizga, ki vsebuje raztopino adalimumaba.
• Merkel cell carcinoma (a type of skin cancer) 
• karcinom Merklovih celic (tip kožnega raka)
N/A N/A *** p < 0.001 for all comparisons between Humira and placebo * p < 0.05 for all comparisons between Humira and placebo N/A not applicable 
*** p < 0,001 za vse primerjave med zdravilom Humira in placebom * p < 0,05 za vse primerjave med zdravilom Humira in placebom np ne pride v poštev
Gently pull the needle cover straight off with the other hand. 
Z drugo roko nežno odstranite pokrovček igle.
The recommended dose of Humira is 20 mg every other week. 
Priporočeni odmerek zdravila Humira je 20 mg vsak drugi teden.
• eye infections 
• okužba oči
Patients in steroid-free remission for >=90 days 
Bolniki v remisiji brez steroidov za ≥ 90 dnia
• nerve root compression (including low back pain and leg pain); 
• stisnenje živčnih korenin (vključno z bolečino v spodnjem delu hrbta in nogah);
The Humira pre-filled pen is a single-use grey and plum-coloured pen which contains a glass syringe with Humira. 
Napolnjeni injekcijski peresnik zdravila Humira je peresnik sive in škrlatne barve za enkratno uporabo, ki vsebuje stekleno brizgo z zdravilom Humira.
In CD Study I and CD Study II, statistically significant improvement in the disease-specific inflammatory bowel disease questionnaire (IBDQ) total score was achieved at Week 4 in patients randomised to Humira 80/40 mg and 160/80 mg compared to placebo and was seen at Weeks 26 and 56 in CD Study III as well among the adalimumab treatment groups compared to the placebo group. 
V študiji Crohnove bolezni I in študij Crohnove bolezni II je bilo v 4. tednu doseženo statistično pomembno izboljšanje skupnega rezultata za bolezen specifičnega vprašalnika za vnetno bolezen črevesa (IBDQ-inflammatory bowel disease questionanaire-) pri bolnikih, ki so bili randomizirani na zdravilo Humira 80/40 mg in 160/80 mg v primerjavi s placebom.
• sicca syndrome (including dry eyes and dry mouth) 
• Sjögrenov sindrom (vključno s suhimi očmi in suhimi usti)
Humira is used to treat polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis. 
Zdravilo Humira se uporablja za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa in artritisa, povezanega z entezitisom.
• low blood measurements for phosphate 
• nizke krvne vrednosti za fosfat
• You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Humira treatment. 
• Premisliti morate o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še 5 mesecev po zadnjem zdravljenju z zdravilom Humira.
In patients with polyarticular juvenile idiopathic arthritis who were 4 to 17 years, anti-adalimumab antibodies were identified in 15.8% (27/171) of patients treated with adalimumab. 
Med bolniki s poliartikularnim juvenilnim idiopatskim artritisom, ki so bili stari od 4 do 17 let, so protitelesa proti adalimumabu ugotovili pri 15,8 % (27/171) bolnikov, ki so dobivali adalimumab.
Table 11: Efficacy Results at 12 Weeks, HS Studies I and II 
Preglednica 11: Rezultati učinkovitosti v 12. tednu, HS študiji I in II Študija HS I
• Psoriatic arthritis, 
• psoriatični artritis,
You can press a cotton ball or a piece of gauze over the injection site for 10 seconds. 
S kosmom vate ali koščkom gaze lahko 10 sekund pritiskate na mesto injiciranja.
• sensation disorders such as tingling, prickling or numbness 
• otežkočeno spanje • motnje v občutenju kot so ščemenje, zbadanje ali omrtvelost
• liquid is cloudy, discoloured, or has flakes or particles in it 
• je tekočina motna, je spremenila barvo ali vsebuje kosmiče ali delce,
• Tuberculosis can develop during therapy even if your child has received treatment for the prevention of tuberculosis. 
• Tuberkuloza se lahko razvije med zdravljenjem, tudi če je vaš otrok prejel preventivno zdravljenje za tuberkulozo.
Note: P = Placebo (Number at Risk); H = HUMIRA (Number at Risk). 
Opomba: P = placebo (število rizičnih preiskovancev); H = HUMIRA (število rizičnih preiskovancev).
Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least five months after the last Humira treatment. 
Ženske v rodni dobi morajo premisliti o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še pet mesecev po zadnjem zdravljenju z zdravilom Humira.
In CD Study II, 325 patients who had lost response or were intolerant to infliximab were randomised to receive either 160 mg Humira at Week 0 and 80 mg at Week 2 or placebo at Weeks 0 and 2. 
V študiji Crohnove bolezni II je bilo 325 bolnikov, ki so postali neodzivni ali so imeli intoleranco na infliksimab, randomiziranih, da so prejeli ali 160 mg zdravila Humira v 0. tednu in 80 mg v 2. tednu ali placebo v 0. in 2. tednu.
Heart failure 
Težave s srcem
What Humira is and what it is used for What you need to know before you use Humira How to use Humira 
Kaj je zdravilo Humira in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Humira Kako uporabljati zdravilo Humira
Patients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with Humira. 
Bolnikom je treba naročiti, naj poiščejo zdravniško pomoč, če med zdravljenjem z zdravilom Humira ali po njem doživijo znake ali simptome, ki nakazujejo tuberkulozno okužbo (npr. trdovraten kašelj, hujšanje/izgubljanje telesne mase, nekoliko zvišano telesno temperaturo, ravnodušnost).
Following the administration of 24 mg/m2 (up to a maximum of 40 mg) subcutaneously every other week to patients with enthesitis-related arthritis who were 6 to 17 years, the mean trough steady-state (values measured at Week 24) serum adalimumab concentrations were 8.8 ± 6.6 μg/ml for adalimumab without concomitant methotrexate and 11.8 ± 4.3 μg/ml with concomitant methotrexate. 
Po dajanju 24 mg/m2 (do največ 40 mg) subkutano vsak drugi teden bolnikom z artritisom, povezanim z entezitisom, ki so bili stari od 6 do 17 let, je bila povprečna najmanjša koncentracija adalimumaba v serumu v stanju dinamičnega ravnovesja (vrednost merjena v 24. tednu) 8,8 ± 6,6 μg/ml med uporabo adalimumaba brez metotreksata in 11,8 ± 4,3 μg/ml med sočasno uporabo metotreksata.
CD Study II: Infliximab Experienced Patients 
Študija Crohnove bolezni II: bolniki, ki so že prejemali infliksimab
Humira may be available as a vial, a pre-filled syringe and/or a pre-filled pen. 
Zdravilo Humira je lahko na voljo tudi kot viala, napolnjena injekcijska brizga in/ali napolnjen injekcijski peresnik.
Table 12 Ped ACR 30 Responses in the JIA study 
Preglednica 12 Odzivi »Ped ACR« 30 v študiji pri juvenilnem idiopatskem artritisu
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Humira therapy. 
Za pediatrične bolnike je priporočljivo, da pred začetkom zdravljenja z zdravilom Humira opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje, če je le mogoče.
Table 17: Efficacy Results at 12 Weeks, HS Studies I and II 
Preglednica 17: Rezultati učinkovitosti v 12. tednu, HS študiji I in II Študija HS I
Non-serious allergic reactions associated with Humira were uncommon during clinical trials. 
Humira povezane alergijske reakcije, ki niso bile resne, so se v kliničnih študijah pojavljale občasno.
Both studies demonstrated an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 1). 
V obeh študijah je bil dokazan zgodnji in vzdrževan učinek zdravila Humira na odstotek neuspeha zdravljenja proti placebu (glejte sliko 1).
• Your child should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Humira treatment. 
• Vaš otrok mora premisliti o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še 5 mesecev po zadnjem zdravljenju z zdravilom Humira.
Humira/MTX n=268 
Zdravilo Humira/MTX n = 268
study V was the percent of patients who achieved an ACR 50 response at Week 52. 
52. tedna dosegli odziv ACR 50.
• increased uric acid in the blood 
• povečana sečna kislina v krvi
Tel.:+36 1 455 8600 
MagyarországAbbVie Kft. Tel.:+36 1 455 8600
In the open-label extension of RA study V, the mean change from baseline at Year 10 in the modified Total Sharp Score was 10.8, 9.2 and 3.9 in patients originally randomized to methotrexate monotherapy, Humira monotherapy and Humira/methotrexate combination therapy, respectively. 
V odprtem podaljšanju študije revmatoidnega artritisa V je bila povprečna sprememba celotne Sharpove ocene v 10. letu pri bolnikih, ki so jih na začetku randomizirali na monoterapijo z metotreksatom, monoterapijo z zdravilom Humira in kombinacijo zdravila Humira/metotreksat, glede na izhodišče 10,8, 9,2 oz. 3,9.
• injection site reactions (including pain, swelling, redness or itching) 
• reakcije na mestu injiciranja (vključno z bolečino, oteklostjo, pordelostjo ali srbenjem)
Polyarticular juvenile idiopathic arthritis from 2 years of age 
Juvenilni idiopatski artritis Poliartikularni juvenilni idiopatski artritis od 2. leta starosti
ACR 50 Week 12 Week 24 
ACR 50 12. teden 24. teden np np
What Humira is and what it is used for What you need to know before your child uses Humira How to use Humira 
Kaj je zdravilo Humira in za kaj ga uporabljamo Kaj morate vedeti, preden bo vaš otrok uporabil zdravilo Humira Kako uporabljati zdravilo Humira
Patients received either placebo or 
ki so prejemali placebo.
• musculoskeletal pain 
• mišičnoskeletna bolečina
The recommended dose of Humira is an initial dose of 20 mg, followed by 20 mg one week later. 
Priporočeni odmerek zdravila Humira je začetni odmerek 20 mg, ki mu sledi 20 mg en teden kasneje.
The 1 pre-filled pen pack comes with 2 alcohol pads (1 spare). 
Pakiranje z 1 napolnjenim injekcijskim peresnikom ima priložena 2 alkoholna zloženca (1 dodatni).
Serious adverse reactions have been reported for Humira. 
Poročali so tudi o resnih neželenih učinkih v zvezi z zdravilom Humira.
Statistically significant increases (improvement) from Baseline to Week 26 and 52 in Body Mass Index and height velocity were observed for both treatment groups. 
V obeh skupinah so opazili statistično pomembno povečanje (izboljšanje) indeksa telesne mase in hitrosti rasti od začetka študije do 26. in 52. tedna.
The recommended dose of Humira is an initial dose of 40 mg, followed by 40 mg one week later. 
Priporočeni odmerek zdravila Humira je začetni odmerek 40 mg, ki mu sledi 40 mg en teden kasneje.
Table 16 Ps Study IV Efficacy Results at 16, 26 and 52 Weeks 
Rezultati učinkovitosti po 16, 26 in 52 tednih
Neurological infections (including viral meningitis), opportunistic infections and tuberculosis (including coccidioidomycosis, histoplasmosis and mycobacterium avium complex infection), bacterial infections, eye infections, diverticulitis 
oportunistične okužbe in tuberkuloza (vključno s kokcidioidomikozo, histoplazmozo in kompleksno okužbo z Mycobacterium avium), bakterijske okužbe,
• Do not use the pre-filled syringe if it has been dropped or crushed 
• Napolnjene injekcijske brizge ne uporabite, če je padla ali se zdrobila
Humira treated patients demonstrated statistically significant improvement in physical function as assessed by HAQ and Short Form Health Survey (SF 36) compared to placebo at Week 24. 
Ob zdravljenju z zdravilom Humira so v primerjavi s placebom 24. teden ugotovili statistično značilno izboljšanje telesnega delovanja, ocenjeno s HAQ in vprašalnikom SF 36 (Short Form Health Survey).
If you do not respond well enough to these medicines, you will be given Humira to reduce the signs and symptoms of your disease. 
Če se nanje ne boste odzvali dovolj dobro, boste dobili zdravilo Humira za zmanjšanje znakov in simptomov vaše bolezni.
Following the administration of 0.8 mg/kg (up to a maximum of 40 mg) subcutaneously every other week to paediatric patients with chronic plaque psoriasis, the mean ± SD steady-state adalimumab trough concentration was approximately 7.4 ± 5.8 µg/ml (79% CV). 
Po dajanju adalimumaba 0,8 mg/kg (do največ 40 mg) subkutano vsak drugi teden pediatričnim bolnikom s kronično psoriazo v plakih, so bile povprečne koncentracije adalimumaba v stanju dinamičnega ravnovesja približno 7,4 ± 5,8 µg/ml (79 % KV).
Health-related quality of life and physical function were assessed using the HAQ-S and the SF-36 questionnaires. 
Z zdravjem povezano kakovost življenja in telesno funkcijo so ocenjevali s pomočjo vprašalnikov
• severe allergic reaction with shock 
• huda alergijska reakcija s šokom
If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor. 
Če se vašemu otroku med zdravljenjem ali po njem pojavijo nove spremembe na koži, ali če se spremeni videz obstoječih sprememb, morate to povedati zdravniku.
• skin cancer 
• kožni rak
Of these skin cancers, squamous cell carcinomas occurred at rates (95% confidence interval) of 2.7 (1.4, 5.4) per 1,000 patient-years among Humira-treated patients and 0.6 (0.1, 4.5) per 1,000 patientyears among control patients. 
Med temi kožnimi raki je bil delež (95 % interval zaupanja) skvamocelularnega karcinoma 2,7 (1,4; 5,4) na 1000 bolnikov-let med bolniki, ki so dobivali zdravilo Humira, in 0,6 (0,1; 4,5) na 1000 bolnikov-let v kontrolni skupini bolnikov.
Humira 40 mg weekly N = 70 
Humira 40 mg vsak teden N = 70
• If you have mild heart failure and you are being treated with Humira, your heart failure status must be closely monitored by your doctor. 
• Če imate blago srčno popuščanje in ste zdravljeni z zdravilom Humira, mora vaš zdravnik vaše stanje okvare srca skrbo nadzirati.
40 mg Humira every week 
40 mg zdravila Humira vsak teden
• Always keep the pre-filled syringe and the special disposal container out of the sight and reach of children 
• Vedno shranjujte napolnjen injekcijski peresnik in poseben zabojnik nedosegljivo otrokom.
Both studies demonstrated an early and sustained effect of Humira on the treatment failure rate versus placebo (see Figure 2). 
V obeh študijah je bil dokazan zgodnji in vzdrževan učinek zdravila Humira na odstotek neuspeha zdravljenja proti placebu (glejte sliko 2).
At Week 16, more patients randomised to Humira 0.8 mg/kg had positive efficacy responses (e.g., PASI 75) than those randomised to 0.4 mg/kg eow or MTX. 
V 16. tednu se je več bolnikov, ki so bili randomizirani na zdravilo Humira 0,8 mg/kg, pozitivno odzvalo v smislu učinkovitosti (npr. PASI 75) kot tistih, ki so bili randomizirani na odmerek 0,4 mg/kg vsak drugi teden ali metotreksat.
The blinded period was followed by an open − label period during which patients received Humira 40 mg every other week subcutaneously for up to an additional 28 weeks. 
Slepljenemu obdobju je sledilo odprto obdobje, med katerim so bolniki dobivali 40 mg zdravila Humira vsak drugi teden subkutano, do največ dodatnih 28 tednov.
In RA study V with early rheumatoid arthritis patients who were methotrexate naïve, combination therapy with Humira and methotrexate led to faster and significantly greater ACR responses than methotrexate monotherapy and Humira monotherapy at Week 52 and responses were sustained at Week 104 (see Table 
V študiji revmatoidnega artritisa V pri bolnikih z zgodnjim revmatoidnim artritisom, ki še niso dobivali metotreksata, je kombinirana terapija z zdravilom Humira in metotreksatom po 52 tednih prinesla hitrejše in značilno večje odzive ACR kakor monoterapija z metotreksatom ali monoterapija z zdravilom Humira, odzivi pa so se ohranili do 104. tedna (glejte preglednico 10).
• low blood measurements for red blood cells 
• nizke krvne vrednosti za rdeče krvne celice
Throwing away supplies 
Kako zavreči ostanke
If you do not respond well enough to these medicines, you will be given Humira to treat your polyarticular juvenile idiopathic arthritis or enthesitisrelated arthritis. 
Če se na ta zdravila ne odzovete dovolj dobro, boste za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa ali artritisa, povezanega z entezitisom dobili zdravilo Humira.
Clear Liquid in Syringe 
Bistra tekočina v brizgi
• methotrexate 
Metotreksat
Two patients out of 3,441 treated with Humira in all rheumatoid arthritis and psoriatic arthritis studies developed clinical signs suggestive of new-onset lupus-like syndrome. 
V vseh študijah revmatoidnega artritisa in psoriatičnega artritisa so se klinični znaki, ki so nakazovali novonastali lupusni sindrom, pojavili pri 2 od 3441
Place the white needle sleeve straight (90˚ angle) against the injection site. 
Bel tulec z iglo položite pokončno (pod kotom 90°) na mesto injiciranja.
• Enthesitis-related arthritis, 
• artritis, povezan z entezitisom,
In patients not given concomitant methotrexate, the incidence was 16/185 (8.6%), compared to 1/19 (5.3%) when adalimumab was used as add-on to methotrexate. 
Pri bolnikih, ki sočasno niso dobivali metotreksata, je bila incidenca 16/185 (8,6 %), pri tistih, ki so adalimumab uporabljali kot dodatek metotreksatu, pa 1/19